MedPath

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Phase 2
Recruiting
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Drug: Placebo
Registration Number
NCT06588686
Lead Sponsor
Vicore Pharma AB
Brief Summary

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.

Trial website: www.aspire-ipf.com

Detailed Description

Buloxibutid is an oral angiotensin II type 2 (AT2) receptor agonist and has been shown to improve lung function in IPF over 36 weeks.

Buloxibutid agonizes the AT2 receptor on alveolar epithelial type 2 cells (AEC2s), which are believed to play a central role in the disease. Buloxibutid has been demonstrated preclinically to improve AEC2 viability, alveolar integrity via surfactant secretion and epithelial repair via replenishment of gas exchange alveolar epithelial type 1 cells (AEC1s). This leads to decreasing downstream profibrotic signaling, enhancing resolution of existing fibrotic tissue via upregulation of collagenase matrix metalloproteinases, and addressing vascular disfunction associated with the disease.

The trial will include participants who are on stable licensed IPF therapy or who are currently not treated with a licensed IPF therapy. The latter group will include participants intolerant or not responsive to licensed IPF therapies, participants ineligible to receive these therapies, and participants who have voluntarily declined to receive a licensed IPF therapy after being fully informed of the potential benefits and risks of such therapy. Due to the potential risk of drug-drug interactions (DDIs), concomitant treatment with pirfenidone is not allowed in this trial. Participants who are not on antifibrotic therapy at study start may initiate such treatment during the study.

The trial is planned to enroll 270 participants, 90 participants on oral buloxibutid 100 mg BID, 90 participants on oral buloxibutid 50 mg BID, and 90 participants on oral placebo BID for 52 weeks. The treatment will be blinded and treatment allocation will be randomized.

The primary measurement will be based on spirometry, measuring the forced vital capacity (FVC).

The trial consists of 3 consecutive periods: a screening period of up to 6 weeks, a 52-week treatment period, and a follow-up period of 2-4 weeks after the 52-week visit. The study procedures have been planned with focus on optimizing patient convenience while allowing a safe conduct and strict scientific rigor.

Trial website: www.aspire-ipf.com

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
270
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Buloxibutid 100 mg BIDBuloxibutidFor 52 weeks.
Buloxibutid 50 mg BIDBuloxibutidFor 52 weeks.
Placebo BIDPlaceboFor 52 weeks.
Primary Outcome Measures
NameTimeMethod
To evaluate the efficacy of buloxibutid compared to placebo in participants with IPF as assessed by FVCweek 52

• Absolute change from baseline in FVC (mL) at week 52

Secondary Outcome Measures
NameTimeMethod
To further evaluate the effects of buloxibutid on disease progression, respiratory-related hospitalization or death compared to placebo in participants with IPFweek 52

• A composite of the proportion of patients with an absolute FVC percent predicted (FVCpp) decrease from baseline of ≥10%; a respiratory-related hospitalization, or death, up to week 52

Trial Locations

Locations (106)

Integral Health Medical Unit

🇲🇽

San Nicolás De Los Garza, Mexico

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Queen Elizabeth Hospital Birmingham

🇬🇧

Birmingham, United Kingdom

Guy's Hospital

🇬🇧

London, United Kingdom

Royal Brompton Hospital

🇬🇧

London, United Kingdom

Wythenshawe Hospital

🇬🇧

Manchester, United Kingdom

Oxford University Hospitals NHS Trust

🇬🇧

Oxford, United Kingdom

UAB Hospital, School of Medicine/Lung Health Center

🇺🇸

Birmingham, Alabama, United States

Paradigm Clinical Research

🇺🇸

La Mesa, California, United States

Keck Medicine of University of Southern California

🇺🇸

Los Angeles, California, United States

Paradigm Clinical Research Centers, Inc.

🇺🇸

Redding, California, United States

UC Davis Health System

🇺🇸

Sacramento, California, United States

UC San Diego Medical Center - Hillcrest

🇺🇸

San Diego, California, United States

National Jewish Medical and Research Center

🇺🇸

Denver, Colorado, United States

University of Florida Health (UF Health)

🇺🇸

Gainesville, Florida, United States

Clinical Research Specialists

🇺🇸

Kissimmee, Florida, United States

Emory Saint Joseph's Hospital

🇺🇸

Atlanta, Georgia, United States

Endeavor Health - Evanston Hospital

🇺🇸

Evanston, Illinois, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

William Beaumont Hospital - Royal Oak

🇺🇸

Royal Oak, Michigan, United States

Stony Brook University

🇺🇸

Stony Brook, New York, United States

Southeastern Research Center

🇺🇸

Winston-Salem, North Carolina, United States

Cleveland Clinic - Cleveland, Department of Pulmonary Medicine

🇺🇸

Cleveland, Ohio, United States

Oregon Clinic, Pulmonary, Critical Care & Sleep Medicine East

🇺🇸

Portland, Oregon, United States

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Low Country Lung and Critical Care

🇺🇸

North Charleston, South Carolina, United States

Baylor Scott & White Research Institute

🇺🇸

Dallas, Texas, United States

University of Utah, Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

University of Wisconsin Clinical Science Center

🇺🇸

Madison, Wisconsin, United States

IMER Respiratory Medicine Institute

🇦🇷

Córdoba, Cordoba, Argentina

Research Institute of Respiratory Diseases

🇦🇷

San Miguel De Tucumán, Tucuman, Argentina

CEMER Medical Center for Respiratory Diseases

🇦🇷

Buenos Aires, Argentina

Breathe Comprehensive Clinical Health

🇦🇷

Godoy Cruz, Argentina

Emphysema Foundation, Pneumology

🇦🇷

Mar Del Plata, Argentina

Vistalba Health Center

🇦🇷

Mendoza, Argentina

Flinders Medical Centre

🇦🇺

Adelaide, Australia

Concord Repatriation General Hospital, Department of Respiratory Medicine

🇦🇺

Concord, Australia

St Vincent's Hospital, Sydney Ltd.

🇦🇺

Darlinghurst, Australia

Austin Hospital

🇦🇺

Heidelberg, Australia

Royal Prince Alfred Hospital

🇦🇺

Sydney, Australia

The Queen Elizabeth Hospital

🇦🇺

Woodville, Australia

Kepler University Hospital GmbH, Department of Pulmonology

🇦🇹

Linz, Austria

Salzburg Regional Hospital, Department of Pneumology/Respiratory Medicine

🇦🇹

Salzburg, Austria

Hospital Penzing, Department of Respiratory and lung diseases

🇦🇹

Vienna, Austria

Erasme Hospital

🇧🇪

Brussels, Belgium

University Hospitals Saint-Luc

🇧🇪

Brussels, Belgium

University Hospital Center Sart-Tilman

🇧🇪

Liège, Belgium

UCL Mont-Godinne University Hospitals

🇧🇪

Yvoir, Belgium

Kelowna Respiratory & Allergy Clinic

🇨🇦

Kelowna, Canada

Laval Hospital

🇨🇦

Laval, Canada

Pierre-Le Gardeur

🇨🇦

Québec, Canada

Diex Research Trois-Riviere Inc.

🇨🇦

Trois-Rivieres, Canada

Vivantes Hospital Neukoelln

🇩🇪

Berlin, Germany

RuhrlandClinic - Lung Center

🇩🇪

Essen, Germany

University Hospital Freiburg

🇩🇪

Freiburg, Germany

Hannover Medical School, Center for Internal Medicine

🇩🇪

Hannover, Germany

University Hospital Heidelberg, Clinic of Thoracic Medicine Heidelberg GmbH

🇩🇪

Heidelberg, Germany

Immenhausen Lung Hospital

🇩🇪

Immenhausen, Germany

University Hospital Tuebingen

🇩🇪

Tuebingen, Germany

"Sotiria" Chest Diseases Hospital of Athens - Site 2

🇬🇷

Athens, Greece

General Hospital of Chest Diseases "Sotiria" 5th Pulmonology Department - Site 1

🇬🇷

Athens, Greece

University General Hospital "Attikon", 2nd Pulmonary Department

🇬🇷

Athens, Greece

University General Hospital of Heraklion, Pneumonology Clinic

🇬🇷

Heraklion, Greece

University General Hospital of Ioannina

🇬🇷

Ioánnina, Greece

University General Hospital of Patras

🇬🇷

Patras, Greece

General Hospital of Thessaloniki

🇬🇷

Thessaloníki, Greece

University Hospital - Ospedali Riuniti Umberto I - GM Lancisi - G Salesi of Ancona

🇮🇹

Ancona, Italy

Local Healthcare Company Papa Giovanni XXIII (ASST Papa Giovanni XXIII)

🇮🇹

Bergamo, Italy

University Polyclinic Hospital of Modena

🇮🇹

Modena, Italy

San Gerardo of Tintori IRCCS Foundation

🇮🇹

Monza, Italy

Foundation PTV - Polyclinic Tor Vergata

🇮🇹

Roma, Italy

University Hospital City of Health and Science of Turin - Hospital Molinette

🇮🇹

Turin, Italy

Soon Chun Hyang Central Medical Center

🇰🇷

Bucheon, Korea, Republic of

The Catholic University Of Korea Bucheon St. Mary's Hospital

🇰🇷

Bucheon, Korea, Republic of

Inje University Busan Paik Hospital

🇰🇷

Busan, Korea, Republic of

InJe University Haeundae Paik Hospital

🇰🇷

Busan, Korea, Republic of

Hanyang University - Myongji Hospital

🇰🇷

Goyang-si, Korea, Republic of

Korea University Anam Hospital

🇰🇷

Seoul, Korea, Republic of

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System

🇰🇷

Seoul, Korea, Republic of

Soon Chun Hyang University Hospital Seoul

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center

🇰🇷

Seoul, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

National Institute of Respiratory Diseases Ismael Cosio Villegas (INER)

🇲🇽

Mexico City, Mexico

Dr. Jose Eleuterio Gonzalez Monterrey University Hospital

🇲🇽

Monterrey, Mexico

Oaxaca Site Management Organization S.C - (Osmo)

🇲🇽

Oaxaca, Mexico

Integral Health Medical Unit

🇲🇽

San Nicolás De Los Garza, Mexico

MICS Medical Centre Bydgoszcz

🇵🇱

Bydgoszcz, Poland

VITAMED Galaj i Cichomski General Partnership

🇵🇱

Bydgoszcz, Poland

Twoja Przychodnia Medical Centre of Nowa Sol

🇵🇱

Nowa Sól, Poland

Allergology- Pulmunology Outpatient Clinic Alergopneuma, Pulmonology Outpatient Clinic

🇵🇱

Świdnik, Poland

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Far Eastern Memorial Hospital

🇨🇳

New Taipei City, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

National Cheng Kung University Hospital

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Queen Elizabeth Hospital Birmingham

🇬🇧

Birmingham, United Kingdom

Guy's Hospital

🇬🇧

London, United Kingdom

Royal Brompton Hospital

🇬🇧

London, United Kingdom

Wythenshawe Hospital

🇬🇧

Manchester, United Kingdom

Oxford University Hospitals NHS Trust

🇬🇧

Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath